Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Sold as Eydenzelt. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Aflibercept-Boav (sold as Eydenzelt), first approved Oct 2, 2025, with 0 new uses approved and 2 published complete response letters.
First approved in Japan 156 months before the US. PMDA's English list since 2008, matched by ingredient; see all Japanese approvals
Eylea, new approvalA drug in a new dosage form indicated for the treatment of age-related macular degeneration associated with subfoveal choroidal neovascularization and… · Bayer Yakuhin, Ltd. · Jan 18, 2024
EyleaA drug with a new indication and a new dosage for the treatment of retinopathy of prematurity. · Bayer Yakuhin, Ltd. · Sep 26, 2022 · Review report
EyleaDrugs with a new indication and a new dosage for the treatment of neovascular glaucoma. · Bayer Yakuhin, Ltd. · Mar 25, 2020
EyleaDrugs with a revised indication for the treatment of macular edema following retinal vein occlusion. · Bayer Yakuhin, Ltd. · Jun 26, 2015 · Review report
EyleaDrugs with a new additional indication and a new dosage for the treatment of diabetic macular edema. · Bayer Yakuhin, Ltd. · Nov 18, 2014
EyleaDrugs with a new additional indication for the treatment of choroidal neovascularization in patients with pathologic myopia. · Bayer Yakuhin, Ltd. · Sep 19, 2014
EyleaDrugs with a new additional indication and a new dosage for the treatment of macular edema following central retinal vein occlusion. · Bayer Yakuhin, Ltd. · Nov 22, 2013
Eylea, new ingredientDrugs with a new active ingredient indicated for the treatment of age-related macular degeneration associated with subfoveal choroidal neovascularization. · Bayer Yakuhin, Ltd. · Sep 28, 2012
Applications
NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
